STRENGTHENING THE HEALTH SYSTEMS RESPONSE TO COVID-19

Community Pharmacy
(1 May 2020)
Address requests about publications of the WHO Regional Office for Europe to:
Publications
WHO Regional Office for Europe
UN City, Marmorvej 51
DK-2100 Copenhagen Ø, Denmark
Alternatively, complete an online request form for documentation, health information, or for permission to quote or translate, on the Regional Office website (http://www.euro.who.int/pubrequest).

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. (http://www.wipo.int/amc/en/mediation/rules/)


Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.
Introduction

This paper is one of a set of technical guidance papers developed by the WHO Regional Office for Europe to provide practical information and resources for decision-makers on measures to strengthen the health system response to COVID-19.

The purpose of this paper is to support pharmacists and other staff working in community pharmacies with guidance on the issues raised by the COVID-19 outbreak.

This paper supports the operationalization of the policy recommendations for the WHO European Region on strengthening the health system response to COVID-19, focusing on policy recommendation No. 11 (Table 1).

Table 1. Summary of 16 health system recommendations to respond to COVID-19

<p>| | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Expand capacity for communication and proactively manage media relations.</td>
<td>2.</td>
<td>Bolster capacity of essential public health services to enable emergency response.</td>
</tr>
<tr>
<td>3.</td>
<td>Clarify first-point-of-contact strategy for possible COVID-19 cases: phone, online, physical.</td>
<td>4.</td>
<td>Protect other potential first contact health system entry points.</td>
</tr>
<tr>
<td>7.</td>
<td>Maintain continuity of essential services while freeing up capacity for COVID-19 response.</td>
<td>8.</td>
<td>Train, repurpose and mobilize the health workforce according to priority services.</td>
</tr>
<tr>
<td>9.</td>
<td>Protect the physical health of frontline health workers.</td>
<td>10.</td>
<td>Anticipate and address the mental health needs of the health workforce.</td>
</tr>
<tr>
<td>11.</td>
<td><strong>Review supply chains and stocks of essential medicines and health technologies.</strong></td>
<td>12.</td>
<td>Mobilize financial support and ease logistical and operational barriers.</td>
</tr>
<tr>
<td>15.</td>
<td>Optimize social protection to mitigate the impact of public health measures on household financial security.</td>
<td>16.</td>
<td>Ensure clarity in roles, relationships and coordination mechanisms in health system governance and across government.</td>
</tr>
</tbody>
</table>

Source: *Strengthening the health system response to COVID-19: Policy Brief*

---

The guidance will be updated on a regular basis using best available evidence and emergent country practices in response to the COVID-19 outbreak in the WHO European Region, including knowledge and evidence generated through the joint WHO Regional Office for Europe/EU Commission/European Observatory platform.

During the COVID-19 health crisis, pharmacists are likely to have an enhanced role in supporting health care systems that may be overburdened managing seriously ill patients. Those unwell may first visit a pharmacy to seek professional advice on the management of their symptoms.

This paper does not replace advice provided by national governments or professional pharmacy associations in each country. However, in the absence of specific guidance, pharmacists should consider the following advice.

**Key issues**

Pharmacists and other staff working in community pharmacies must be aware of the signs and symptoms of COVID-19 infection and of the correct referral pathways as advised by national authorities when possible COVID-19 infection is suspected.

Reinforce messages about physical distancing, staying at home, self-isolation and quarantine in line with national recommendations. These requirements may change frequently, and current advice must be provided.

Pharmacists must be aware of national guidance on the appropriate and correct use of masks, when these are recommended, and on how to wash hands properly. Where possible infographics or other materials should be available to the general public.

Pharmacists have an important role in countering misinformation and responding to misleading and false claims about the effectiveness of various treatments for COVID-19. There are no approved treatments for COVID-19. Some medicines are under trial to assess the risks and benefits of their use in COVID-19 infection.

Pharmacists must be aware of and conform with national regulations regarding the appropriate use of personal protective equipment (PPE) in the pharmacy setting.
Recommendations and strategic actions

Pharmacy premises

- Minimize contact with customers and goods to reduce risk of virus transmission.
- Remove items such as toys and gifts from display to reduce touching of objects.
- Make hand sanitizer available for use by customers, especially in areas where contact with people or goods may occur.
- Staff must wash their hands frequently, using soap and water and washing for at least 20 seconds. Where soap and water are not available, hand sanitizer may be used.
- Main contact surfaces in the pharmacy should be cleaned regularly, for example, every two hours, using an approved alcohol-based solution for cleaning.
- Limit the number of customers in the pharmacy at one time. Add floor markings to ensure customers are separated by at least 1.5 metres, especially where there may be a queue to collect medicines or advice.

Hours of work

- The increased demand for medicines and health advice may mean that governments have extended the regular opening hours of pharmacies.
- Consider dividing staff into teams that work different hours/shifts to ensure that there are enough staff in the pharmacy, even if someone gets infected and falls ill on one shift.
- Be aware of the heightened risks of transmitting the virus to family and friends because of your work in the pharmacy.

Medicines supply

- Recommend medicines in line with national guidelines for the management of COVID-19 infection.
- Be aware of problems with supply of commonly used medicines and where possible maintain suitable levels of buffer stocks to ensure supply to regular customers.
- Ensure continuity of supply for chronic medical conditions. Pharmacists must be aware of any special provisions to enable the supply of medicines such as asthma inhalers, contraceptives, antihypertensive medicines and medicines for heart and kidney disease without prescription.
- Fever and body aches and pains are common presentations in COVID-19 infection so painkillers may be requested. Paracetamol is recommended as the agent of choice.
- Consider restricting the quantities of medicines that may be supplied or sold to an individual if there is high demand or known shortages.
• Be aware of national guidance on acceptable substitutions for products in short supply. Substitution of some medicines may require a discussion with the prescribing doctor.

• Special attention should be given to supply where pharmacists have a role in coordinating supply of oxygen cylinders to patients or health care facilities. Shortages are likely.

• Consider increasing home delivery services for prescription and non-prescription medicines. Services may be provided in conjunction with community groups or agencies such as the Red Cross.

• Ensure easy-to-follow written instructions are provided for patients who are unable to visit the pharmacy.

• Be vigilant and report any concerns about suspected substandard and falsified products to appropriate national bodies.

**Hand rub/hand disinfectants/sanitizer**

• Consider limiting quantities of sales of handrub to avoid hoarding by individuals and to maximize access to this important preventive measure.

• Shortages of commercial supplies of hand sanitizer may mean that pharmacies need to prepare products to support and protect their community.

• WHO provides advice on the preparation of two formulations of handrub in their Guide to local production: WHO-recommended handrub formulations, which can be found at: https://www.who.int/gpsc/5may/guide_to_local_production.pdf
Helpful resources

Links to useful resources for pharmacists

WHO


WHO Regional Office for Europe


European Centre for Disease Prevention and Control (ECDC)


Pharmaceutical Group of the European Union (PGEU)

• COVID-19 information hub: https://www.pgeu.eu/covid-19-information-hub/

International Pharmaceutical Federation (FIP)

• Position statement on the association between the use of non-steroidal anti-inflammatory medicines (including ibuprofen), ace inhibitors, angiotensin receptor blockers (ARBs) and corticosteroids, and an increased risk of coronavirus/covid-19 infection or disease severity: https://www.fip.org/files/content/priority-areas/coronavirus/FIP-Position-Statement-COVID-19-medicines.pdf

European Medicines Agency

WHO Regional Office for Europe

The World Health Organization (WHO) is a specialized agency of the United Nations created in 1948 with the primary responsibility for international health matters and public health. The WHO Regional Office for Europe is one of six regional offices throughout the world, each with its own programme geared to the particular health conditions of the countries it serves.

Member States

Albania
Andorra
Armenia
Austria
Azerbaijan
Belarus
Belgium
Bosnia and Herzegovina
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Georgia
Germany
Greece
Hungary
Iceland
Ireland
Israel
Italy
Kazakhstan
Kyrgyzstan
Latvia
Lithuania
Luxembourg
Malta
Monaco
Montenegro
Netherlands
North Macedonia
Norway
Poland
Portugal
Republic of Moldova
Romania
Russian Federation
San Marino
Serbia
Slovakia
Slovenia
Spain
Sweden
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan